Saxsons Group — India's trusted nuclear medicine, radiotherapy, oncosurgery, dosimetry and cyclotron supplier since 1986
Peer-ReviewedPubMedClinical TrialEuropean urology · 2026

Re: Effect of [68Ga]Ga-PSMA-11 PET-CT in the Diagnosis of Prostate Cancer in Men with Equivocal or Clinically High-risk Non-suspicious Findings in Multiparametric MRI (PRIMARY2): A Multicentre, Non-inferiority, Phase 3, Randomised Controlled Trial.

Urso L, Giannarini G, Girometti R, Crestani A, Bauckneht M.

Read on PubMed →doi:10.1016/j.eururo.2026.07.012 →

Identifiers

PubMed ID: 42463362

Radar topics

Ga-68 PSMA PET

Related in the same topic

Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026
Prognostic Value of [<sup>18</sup>F]FDG PET Combined with [<sup>68</sup>Ga]Ga-PSMA PET as Pretreatment Imaging in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with [<sup>177</sup>Lu]Lu-PSMA-617.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026
Clinical Trial Protocol for LPS-Boost: Intensified [<sup>177</sup>Lu]Lu-PSMA-617 Treatment for Patients with Metastatic Castration-Resistant Prostate Cancer with Low PSMA-Expressing Disease.
Research · 2026📖 Free
Using 18F-FDG and 68Ga-PSMA-11 PET/CT to evaluate salivary glands in Sjögren's Disease: Implications for Treatment Stratification
Zeitschrift fur medizinische Physik · 2026
Swiss survey and national diagnostic reference levels for PET/CT examinations in adults.
Lancet (London, England) · 2026
[<sup>177</sup>Lu]Lu-PSMA-617 in patients with PSMA-positive metastatic androgen pathway modulator-naive/sensitive prostate cancer (PSMAddition): a phase 3 randomised, controlled trial.
Radiation protection dosimetry · 2026
Assessment of weight-based variations in effective dose for common PET/CT scans in a tertiary hospital.
Search all papers →More Ga-68 PSMA PET research →